Medicenna Therapeutics Announces Upcoming Presentation at the AACR Annual Meeting 2021
Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) announced the upcoming presentation of a poster at the American Association for Cancer Research (AACR) Annual Meeting 2021. Scheduled for April 10-15, 2021, the poster will focus on preclinical studies of a bispecific Superkine targeting IL-2 and IL-4/IL-13 pathways. The abstract is titled Modulation of Immune Responses to Cancer by Bi-specific IL-2/IL-13 Superkines and will be available for on-demand viewing post-presentation. Medicenna is noted for its innovative approaches in immunotherapy, particularly its lead IL4 Empowered Superkine, MDNA55.
- None.
- None.
TORONTO and HOUSTON, March 11, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the publication of an abstract for an electronic poster that will be presented during Week 1 of the American Association for Cancer Research (AACR) Annual Meeting 2021, taking place virtually from April 10-15, 2021. The poster will describe early preclinical studies evaluating a long-acting bispecific Superkine composed of an IL-2 super-agonist linked to a dual IL-4/IL-13 super-antagonist.
Details of the poster presentation and corresponding abstract are shown below:
Title: Modulation of Immune Responses to Cancer by Bi-specific IL-2/IL-13 Superkines
Session Type: E-Poster Session
Session Title: Immunomodulatory Agents and Interventions
Abstract Number: 1734
The full text of the published abstract is currently available on the AACR Annual Meeting 2021 website. The corresponding poster will be available for on-demand viewing on the AACR Annual Meeting 2021 e-poster website starting at 8:30 am ET on April 10, 2021 and will also be posted to the “Events and Presentations” page of Medicenna’s website following the start of the conference.
About Medicenna
Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines for the treatment of a broad range of cancers. Medicenna’s long-acting IL2 Superkine asset, MDNA11, is a next-generation IL-2 with superior CD122 binding without CD25 affinity and therefore preferentially stimulates cancer killing effector T cells and NK cells when compared to competing IL-2 programs. Medicenna’s lead IL4 Empowered Superkine, MDNA55, has completed a Phase 2b clinical trial for rGBM, the most common and uniformly fatal form of brain cancer. MDNA55 has been studied in five clinical trials involving 132 subjects, including 112 adults with rGBM. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.
Forward-Looking Statement
This news release contains forward-looking statements under applicable securities laws and relate to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects”, “believes” and similar expressions. All statements other than statements of historical fact, included in this release, including the future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the risks detailed in the annual information form of the Company dated May 14, 2020 and in other filings made by the Company with the applicable securities regulators from time to time in Canada and the United States.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect and that study results could change over time as the study is continuing to follow up all subjects and new data are continually being received which could materially change study results. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements only as expressly required by Canadian and United States securities law.
FAQ
What is the significance of the abstract presented by Medicenna at the AACR Annual Meeting 2021?
When will the AACR Annual Meeting 2021 take place?
What are the details of the poster presentation by Medicenna?
Where can I find the abstract for Medicenna's poster presentation?
What is the role of MDNA55 in Medicenna's research?
